

**Table 1: Description of the study population according to treatment group**

	Adefovir (n = 29)	Tenofovir (n = 56)	p
<b>Demographics</b>			
Sex Male/Female (% Males)	28/1 (96.6)	54/2 (96.4)	ns
Age, years (median, SD)	41.5 (7.7)	42.3 (7.2)	ns
Country of origin HBV prevalence > 2% (n, %)	5 (17.2)	9 (16.1)	ns
<b>Characteristics of HIV infection</b>			
Duration of HIV Infection, years (mean, SD)	10.7 (5.3)	10.7 (4.5)	ns
History of an AIDS-defining event (n, %)	5 (17.2)	9 (16.1)	ns
Nb (%) of patients treated with ARV before inclusion patients	26 (89.7)	53 (94.6)	ns
Other ARV treatments associated at baseline			ns
2 NRTI (n, %)	2 (6.9)	4 (7.1)	
1 NRTI + 1 NNRTI (n, %)	3 (10.3)	6 (10.7)	
1 NRTI + 1 PI (n, %)	13 (44.8)	18 (32.1)	
1 NRTI + 1 NNRTI + 1 PI (n, %)	9 (31.0)	28 (50.0)	
CD4 T cell count, per mm <sup>3</sup> (mean, SD)	482 (298)	457 (250)	ns
Rate of HIV-RNA above detection limit (n, %)	14 (53.9)	29 (51.8)	ns
HIV-RNA, log <sub>10</sub> copies/mL (median, IQR)	1.88 (1.70–3.81)	1.84 (1.70-4.14)	ns
<b>Characteristics of HBV infection</b>			
Duration of HBV Infection years (mean, SD)	8.3 (4.6)	7.7 (5.0)	ns
Presence of serum HBe Ag (n, %)	25 (86.2)	50 (89.3)	ns
Presence of serum antiHBe Ab (n, %)	4 (15.4)	6 (10.9)	ns
HBV-DNA, log <sub>10</sub> copies/mL (median, IQR)	8.30 (6.56 – 9.10)	7.30 (6.00 – 8.30)	ns
HCV co-infection (n, %)	3 (10.3)	4 (7.1)	ns
HDV co-infection (n, %)	2 (6.9)	2 (3.6)	ns
History of treatment with lamivudine (n, %)	26 (89.7)	50 (89.3)	ns
Duration of treatment with lamivudine, months (mean, SD)	69.6 (27.8)	63.8 (28.1)	ns
Co-treatment with lamivudine during study (n, %)	19 (65.5)	44 (78.6)	ns
History of treatment with Interferon or PegInterferon (n, %)	5 (17.3)	4 (7.1)	ns
Fibrosis METAVIR score F0-F1 v. F2 v. F3-F4 (n, %)	2 (8.7) – 8 (34.8) – 13 (56.5)	14 (38.9) – 10 (27.8) – 12 (33.3)	0.02
Activity METAVIR score A0-A1 v. A2 v. A3 (n, %)	22 (52.2) – 9 (39.1) – 2 (8.7)	22 (61.1) – 11 (30.6) – 3 (8.3)	ns
YMDD mutants, n=75 (n, %)	21 (91.3)	39 (75.0)	ns
Pre Core mutants (W28 mutation), n=65 (n, %)	3 (30.0)	9 (16.4)	ns
ALT IU/mL (mean, SD)	134 (150)	90 (93)	ns

Continuous variables compared using two-tailed *t*-test; categorical variables compared using Pearson's chi-square statistics (with continuity-corrected chi-square statistics where appropriate).

**Table 2: 12 month evolution of biochemical and virological parameters according to treatment groups**

	ADV group (n = 29)			TDF group (N = 56)		
	baseline	12 months	p	baseline	12 months	p
HBV-DNA log <sub>10</sub> copies/mL, median (Q1 - Q3) <sup>1</sup>	8.30 (6.56 - 9.10)	3.87 (2.95 - 5.60)	<0.0001	7.30 (6.00 - 8.30)	2.47 (2.30 - 3.52)	<0.0001
Presence of HBe Antigen (n, %) <sup>2</sup>	21 (87.5)	17 (70.8)	0.02	47 (88.7)	40 (75.5)	0.002
Presence of antiHBe Antibody (n, %) <sup>2</sup>	4 (20.0)	5 (25.0)	0.001	6 (11.5)	8 (15.4)	<0.001
ALT IU/L, mean (SD) <sup>1</sup>	134 (150)	83 (79)	ns	90 (93)	46 (29)	0.001
AST IU/L, mean (SD) <sup>1</sup>	112 (102)	72 (80)	ns	66 (74)	33 (11)	0.001
g-Glutamyl Transferase IU/L, mean (SD) <sup>3</sup>	136 (223)	74 (75)	ns	81 (95)	60 (67)	ns
ALP IU/L, mean (SD) <sup>3</sup>	104 (63)	101 (57)	ns	85 (33)	79 (24)	ns
Creatinine Clearance ml/min, mean (SD) <sup>3</sup>	103.8 (17.8)	94.2 (19.5)	0.02	95.3 (32.5)	100.0 (23.2)	ns
CD4+ cell count/mm <sup>3</sup> , mean (SD) <sup>3</sup>	482 (298)	488 (402)	ns	457 (250)	501 (238)	0.01
HIV-RNA log <sub>10</sub> copies/mL, median (IQR) <sup>1</sup>	1.88 (1.70-5.20)	1.70 (1.70-5.67)	ns	1.85 (1.70-6.19)	1.70 (1.70-3.84)	<0.0001

<sup>1</sup> Wilcoxon signed-rank test ; <sup>2</sup> Fisher's Exact Test ; <sup>3</sup> Two-tailed paired t-test

**Table 3: Factors influencing the time to undetectability (HBV-DNA < 200 copies / mL), univariate analysis.**

	<b>Crude Hazard Ratio</b>	<b>CI 95%</b>	<b>p</b>
TDF v. ADV	2.22	(0.99-4.94)	0.05
HBV load at baseline			
- per log <sub>10</sub> copies/mL HBV-DNA	0.66	(0.55-0.80)	<0.001
- < 2000 copies/mL	1.00	**	**
- 2000 – 10,000 copies/mL	0.12	(0.03-0.46)	0.002
- > 10,000 copies/mL	0.05	(0.02-0.14)	<0.001
Presence of HBe antigen in serum	0.13	(0.04-0.41)	<0.001
Presence of YMDD mutation	0.77	(0.29-2.07)	0.6
Presence of Pre C mutation	0.60	(0.28-1.28)	0.2
HIV load at baseline (per log <sub>10</sub> HIV-RNA)	0.85	(0.47-1.54)	0.6
Duration of HIV infection (per year)	0.95	(0.88-1.02)	0.14
CD4+ Cell Count (≥ 402 /mm <sup>3</sup> )	0.74	(0.42-1.31)	0.3
METAVIR Fibrosis F0-F2 vs F3-F4	1.72	(0.78-3.79)	0.2
ALT level at baseline (≥72 UI/mL = median)	0.46	(0.25-0.85)	0.01
Additional HCV co-infection	1.42	(0.44-4.58)	0.6
Alcohol consumption (cut at the median)	0.71	(0.40-1.29)	0.3

**Table 4: Multivariate analysis of factors influencing the time to HBV-DNA undetectability (<200copies/mL)**

	<b>Adjusted Hazard Ratio</b>	<b>CI 95%</b>	<b>p</b>
TDF v. ADV	2.79	(1.05-7.40)	0.039
HBV load at baseline (per log <sub>10</sub> copies/mL HBV-DNA)	0.75	(0.59-0.94)	0.01
ALT level at baseline (≥72 UI/mL = median)	0.58	(0.32-1.05)	0.07
Presence of HBe antigen in serum	0.20	(0.05-0.79)	0.02